Project Grant R01CA303051
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $643K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $432,050 on August 17, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop peptide-MHC pseudotyped retroviral vectors for in vivo gene delivery to antigen-specific T cells as a novel cancer immunotherapy approach. The work addresses a gap in current cancer immunotherapies by combining attributes of CAR-T cell therapies with tumor-infiltrating lymphocyte and immune checkpoint blockade...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc., $454,109 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a novel approach for reprogramming tumor-associated macrophages using theranostic nanoparticles combined with radiation therapy to stimulate the body's immune system to treat cancer. Preliminary results demonstrate that nanoparticles combined with radiation can reprogram pro-tumor macrophages into an anti-tumor phenotype...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $606,749 on August 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate novel functions of cell cycle proteins in G1/S phase progression and cancer. The research examines the molecular roles of the cyclin B–CDK1 kinase complex in regulating cell cycle entry and DNA synthesis. Aim 1 uses mouse and human cells to identify the range of molecular functions played by cyclin B–CDK1 during G1/S phase....
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $609,130 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate TRIM28 inhibition as a synthetic lethal strategy for small cell lung cancers with NOTCH2-inactivation. The research will use syngeneic immunocompetent mouse models of small cell lung cancer to test whether TRIM28 inhibition restores anti-tumor immune responses in NOTCH2-mutant tumors. The work builds on prior...
- The National Cancer Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $134,919 under the Cancer Research Manpower program (CFDA 93.398) on June 11, 2026. The award funds structure-function and mechanistic studies of the protein-O-mannosyl transferase (POMT) complex in pediatric low-grade gliomas driven by the KIAA1549:BRAF fusion. The research aims to determine high-resolution structures of the POMT...
- The National Cancer Institute awarded Dana-Farber Cancer Institute, Inc. $528,099 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize therapeutic vulnerabilities in ovarian clear cell carcinoma and develop new treatment strategies for both ARID1A-mutant and ARID1A-wildtype disease. The funded research identifies the PI3K/mTOR and HIF/VEGF pathways as fundamental therapeutic targets in ovarian clear cell carcinoma, with particular focus on synergy...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...